Abstract
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease. It has been identified that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids can be essential risk factors for developing complications such as upper gastrointestinal bleeding (UGIB).
Objective: This study aimed to describe the safety profile of drugs used to treat RA focused in UGIB.
Methods: A cross-sectional study of patients with RA between 2015 and 2021, a description of the population, and an evaluation of the relationship with UGIB through bivariate analysis and logistic regression.
Results: Of 405 individuals, 16 presented UGIB (93.8% women, mean age was 65±13.6 years). No statistically significant differences were found regarding UGIB and medication use, except for the mean dose of corticosteroids. In the multivariate analysis, it was found that the presence of anemia in the last three months had an adjusted OR (AOR) of 16.1 (95% CI 2.74- 24.23) and higher HAQ values during the previous three months had an AOR of 6.17 (95% CI 1.79- 21.24).
Conclusion: This study found a low frequency of UGIB in patients with RA. More significant disability and anemia in the previous months were independently associated with UGIB. The low frequency of NSAID use in this population is noteworthy. In general, reasonable medication use related to this complication is recommended.
Keywords: Rheumatoid arthritis, upper gastrointestinal bleeding, safety, non-steroidal anti-inflammatory drugs, corticosteroids, multivariate analysis.
Graphical Abstract
[1]
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016; 388(10055): 2023-38.
[http://dx.doi.org/10.1016/S0140-6736(16)30173-8] [PMID: 27156434]
[http://dx.doi.org/10.1016/S0140-6736(16)30173-8] [PMID: 27156434]
[2]
Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: Estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014; 73(7): 1316-22.
[http://dx.doi.org/10.1136/annrheumdis-2013-204627] [PMID: 24550173]
[http://dx.doi.org/10.1136/annrheumdis-2013-204627] [PMID: 24550173]
[3]
Myasoedova E, Matteson EL, Talley NJ, Crowson CS. Increased incidence and impact of upper and lower gastrointestinal events in patients with rheumatoid arthritis in Olmsted County, Minnesota: A longitudinal population-based study. J Rheumatol 2012; 39(7): 1355-62.
[http://dx.doi.org/10.3899/jrheum.111311] [PMID: 22467929]
[http://dx.doi.org/10.3899/jrheum.111311] [PMID: 22467929]
[4]
Bassotti G, Gaburri M, Biscarini L, et al. Oesophageal motor activity in rheumatoid arthritis: A clinical and manometric study. Digestion 1988; 39(3): 144-50.
[http://dx.doi.org/10.1159/000199618] [PMID: 3208998]
[http://dx.doi.org/10.1159/000199618] [PMID: 3208998]
[5]
Schneider A, Merikhi A, Frank BB. Autoimmune disorders: Gastrointestinal manifestations and endoscopic findings. Gastrointest Endosc Clin N Am 2006; 16(1): 133-51.
[http://dx.doi.org/10.1016/j.giec.2006.01.013] [PMID: 16546029]
[http://dx.doi.org/10.1016/j.giec.2006.01.013] [PMID: 16546029]
[6]
Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: A systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35(12): 1127-46.
[http://dx.doi.org/10.1007/BF03261999] [PMID: 23137151]
[http://dx.doi.org/10.1007/BF03261999] [PMID: 23137151]
[7]
Hernández-Díaz S, Rodríguez LAG. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160(14): 2093-9.
[http://dx.doi.org/10.1001/archinte.160.14.2093] [PMID: 10904451]
[http://dx.doi.org/10.1001/archinte.160.14.2093] [PMID: 10904451]
[8]
Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: A systematic review and meta-analysis. BMJ Open 2014; 4(5): e004587.
[http://dx.doi.org/10.1136/bmjopen-2013-004587] [PMID: 24833682]
[http://dx.doi.org/10.1136/bmjopen-2013-004587] [PMID: 24833682]
[9]
Machado J, Ruiz A, Machado-Duque M. Adverse drug reactions associated with the use of disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Value Health 2015; 18(3): A153.
[http://dx.doi.org/10.1016/j.jval.2015.03.891]
[http://dx.doi.org/10.1016/j.jval.2015.03.891]
[10]
Machado-Duque ME, Ramírez-Valencia DM, Murillo-Muñoz MM, Machado-Alba JE. Trends in opioid use in a cohort of patients with rheumatoid arthritis. Pain Res Manag 2020; 2020: 1-6.
[http://dx.doi.org/10.1155/2020/3891436] [PMID: 32724487]
[http://dx.doi.org/10.1155/2020/3891436] [PMID: 32724487]
[11]
Lanas A, Boers M, Nuevo J. Gastrointestinal events in at-risk patients starting Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for rheumatic diseases: The EVIDENCE study of European routine practice. Ann Rheum Dis 2015; 74(4): 675-81.
[http://dx.doi.org/10.1136/annrheumdis-2013-204155] [PMID: 24351518]
[http://dx.doi.org/10.1136/annrheumdis-2013-204155] [PMID: 24351518]
[12]
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62(9): 2569-81.
[http://dx.doi.org/10.1002/art.27584] [PMID: 20872595]
[http://dx.doi.org/10.1002/art.27584] [PMID: 20872595]
[13]
Fransen J, Stucki G, van Riel PLCM. Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Rheum 2003; 49(S5): S214-24.
[http://dx.doi.org/10.1002/art.11407]
[http://dx.doi.org/10.1002/art.11407]
[14]
Esteve-Vives J, Batlle-Gualda E, Reig A. Spanish version of the Health Assessment Questionnaire: Reliability, validity and transcultural equivalency. Grupo para la Adaptación del HAQ a la Población Española. J Rheumatol 1993; 20(12): 2116-22.
[PMID: 8014941]
[PMID: 8014941]
[15]
Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther 2010; 32(10): 1240-8.
[http://dx.doi.org/10.1111/j.1365-2036.2010.04465.x] [PMID: 20955443]
[http://dx.doi.org/10.1111/j.1365-2036.2010.04465.x] [PMID: 20955443]
[16]
Luo JC, Leu HB, Huang KW, et al. Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis. CMAJ 2011; 183(18): E1345-51.
[http://dx.doi.org/10.1503/cmaj.110299] [PMID: 22083684]
[http://dx.doi.org/10.1503/cmaj.110299] [PMID: 22083684]
[17]
Peng YL, Leu HB, Luo JC, et al. Diabetes is an independent risk factor for peptic ulcer bleeding: A nationwide population-based cohort study. J Gastroenterol Hepatol 2013; 28(8): 1295-9.
[http://dx.doi.org/10.1111/jgh.12190] [PMID: 23488965]
[http://dx.doi.org/10.1111/jgh.12190] [PMID: 23488965]
[18]
Wara P, Stosdkilde H. Bleeding pattern before admission as guideline for emergency endoscopy. Scand J Gastroenterol 1985; 20(1): 72-8.
[http://dx.doi.org/10.3109/00365528509089635] [PMID: 3992165]
[http://dx.doi.org/10.3109/00365528509089635] [PMID: 3992165]
[19]
Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120(3): 594-606.
[http://dx.doi.org/10.1053/gast.2001.21907] [PMID: 11179238]
[http://dx.doi.org/10.1053/gast.2001.21907] [PMID: 11179238]
[20]
Henry D, Lim LL-Y, Rodriguez L A G, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. BMJ 1996; 312(7046): 1563-6.
[http://dx.doi.org/10.1136/bmj.312.7046.1563] [PMID: 8664664]
[http://dx.doi.org/10.1136/bmj.312.7046.1563] [PMID: 8664664]
[21]
Barbulescu A, Delcoigne B, Askling J, Frisell T. Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: A nationwide cohort study. RMD Open 2020; 6(2): e001201.
[http://dx.doi.org/10.1136/rmdopen-2020-001201] [PMID: 32669452]
[http://dx.doi.org/10.1136/rmdopen-2020-001201] [PMID: 32669452]
[22]
Janssen M, Dijkmans BAC, van der Sluys FA, et al. Upper gastrointestinal complaints and complications in chronic rheumatic patients in comparison with other chronic diseases. Rheumatology 1992; 31(11): 747-52.
[http://dx.doi.org/10.1093/rheumatology/31.11.747] [PMID: 1450796]
[http://dx.doi.org/10.1093/rheumatology/31.11.747] [PMID: 1450796]
[23]
Pok LSL, Shabaruddin FH, Dahlui M, et al. Clinical and economic implications of upper gastrointestinal adverse events in Asian rheumatological patients on long-term non-steroidal anti-inflammatory drugs. Int J Rheum Dis 2018; 21(5): 943-51.
[http://dx.doi.org/10.1111/1756-185X.13256] [PMID: 29314744]
[http://dx.doi.org/10.1111/1756-185X.13256] [PMID: 29314744]
[24]
Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet 2007; 369(9560): 465-73.
[http://dx.doi.org/10.1016/S0140-6736(07)60234-7] [PMID: 17292766]
[http://dx.doi.org/10.1016/S0140-6736(07)60234-7] [PMID: 17292766]
[25]
Chan FKL, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial. Lancet 2010; 376(9736): 173-9.
[http://dx.doi.org/10.1016/S0140-6736(10)60673-3] [PMID: 20638563]
[http://dx.doi.org/10.1016/S0140-6736(10)60673-3] [PMID: 20638563]
[26]
George MD, Baker JF, Winthrop K, et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis. Ann Intern Med 2020; 173(11): 870-8.
[http://dx.doi.org/10.7326/M20-1594] [PMID: 32956604]
[http://dx.doi.org/10.7326/M20-1594] [PMID: 32956604]
[27]
Tsujimoto S, Mokuda S, Matoba K, et al. The prevalence of endoscopic gastric mucosal damage in patients with rheumatoid arthritis. PLoS One 2018; 13(7): e0200023.
[http://dx.doi.org/10.1371/journal.pone.0200023] [PMID: 29985937]
[http://dx.doi.org/10.1371/journal.pone.0200023] [PMID: 29985937]
[28]
Hernández-Díaz S, Rodríguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001; 153(11): 1089-93.
[http://dx.doi.org/10.1093/aje/153.11.1089] [PMID: 11390328]
[http://dx.doi.org/10.1093/aje/153.11.1089] [PMID: 11390328]
[29]
Takatori Y, Kato M, Sunata Y, et al. Impaired activity of daily living is a risk factor for high medical cost in patients of non-variceal upper gastrointestinal bleeding. Surg Endosc 2019; 33(5): 1518-22.
[http://dx.doi.org/10.1007/s00464-018-6433-4] [PMID: 30209605]
[http://dx.doi.org/10.1007/s00464-018-6433-4] [PMID: 30209605]
[30]
Pilotto A, Maggi S, Noale M, Franceschi M, Parisi G, Crepaldi G. Association of upper gastrointestinal symptoms with functional and clinical charateristics in elderly. World J Gastroenterol 2011; 17(25): 3020-6.
[http://dx.doi.org/10.3748/wjg.v17.i25.3020] [PMID: 21799648]
[http://dx.doi.org/10.3748/wjg.v17.i25.3020] [PMID: 21799648]
[31]
Pilotto A. Aging and upper gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2004; 18: 73-81.
[http://dx.doi.org/10.1016/j.bpg.2004.06.015] [PMID: 15588798]
[http://dx.doi.org/10.1016/j.bpg.2004.06.015] [PMID: 15588798]
[32]
Furst DE, Chang H, Greenberg JD, et al. Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: Evidence from the corrona registry. Clin Exp Rheumatol 2009; 27(4): 560-6.
[PMID: 19772785]
[PMID: 19772785]
[33]
Chan FKL, Cryer B, Goldstein JL, et al. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol 2010; 37(1): 167-74.
[http://dx.doi.org/10.3899/jrheum.090168] [PMID: 19884267]
[http://dx.doi.org/10.3899/jrheum.090168] [PMID: 19884267]
[34]
Dottori L, Pivetta G, Annibale B, Lahner E. Update on serum biomarkers in autoimmune atrophic gastritis. Clin Chem 2023; 69(10): 1114-31.
[http://dx.doi.org/10.1093/clinchem/hvad082] [PMID: 37680186]
[http://dx.doi.org/10.1093/clinchem/hvad082] [PMID: 37680186]
[35]
Rooney CM, Mankia K, Mitra S, Moura IB, Emery P, Wilcox MH. Perturbations of the gut microbiome in anti-CCP positive individuals at risk of developing rheumatoid arthritis. Rheumatology 2021; 60(7): 3380-7.
[http://dx.doi.org/10.1093/rheumatology/keaa792] [PMID: 33313854]
[http://dx.doi.org/10.1093/rheumatology/keaa792] [PMID: 33313854]
[36]
Demoruelle MK, Harrall KK, Ho L, et al. Anti-citrullinated protein antibodies are associated with neutrophil extracellular traps in the sputum in relatives of rheumatoid arthritis patients. Arthritis Rheumatol 2017; 69(6): 1165-75.
[http://dx.doi.org/10.1002/art.40066] [PMID: 28182854]
[http://dx.doi.org/10.1002/art.40066] [PMID: 28182854]
[37]
Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100(8): 1685-93.
[http://dx.doi.org/10.1111/j.1572-0241.2005.41833.x] [PMID: 16086703]
[http://dx.doi.org/10.1111/j.1572-0241.2005.41833.x] [PMID: 16086703]
[38]
MacDonald TM, Mackenzie IS, Wei L, Hawkey CJ, Ford I. Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: Protocol of the standard care versus celecoxib outcome trial (SCOT). BMJ Open 2013; 3(1): e002295.
[http://dx.doi.org/10.1136/bmjopen-2012-002295] [PMID: 23364320]
[http://dx.doi.org/10.1136/bmjopen-2012-002295] [PMID: 23364320]
Article Metrics
20
2